The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) [RETIRED]: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Open accessAbstract
The Quality Standards Subcommittee of the American Academy of Neurology is charged with developing practice parameters for neurologists for diagnostic procedures, treatment modalities, and clinical disorders.The selection of topics for which practice parameters are used is based on prevalence, frequency of use, economic impact, membership involvement, controversy, urgency, external constraints, and resources required.This paper addresses the role of thymectomy in the treatment of nonthymomatous autoimmune MG.In 1939, Blalock et al. 1 reported the remission of generalized MG in a 21-year-old woman after removal of a cystic thymic tumor.Subsequently, Blalock et al. 2,3 performed thymectomy on MG patients without thymoma, found hyperplasia in the thymus glands, and reported improvement in at least half of their patients.Since these reports, thymectomy, with or without the presence of thymoma, has gained widespread acceptance as a form of treatment for MG.Because a definitive study of the effectiveness of thymectomy has never been done, 4,5 the role of thymectomy in the management of MG remains uncertain.Nevertheless, physicians have to advise their patients regarding the benefits of thymectomy based on the existing literature.Our goal is to develop evidence-based recommendations for clinicians considering thymectomy for patients with nonthymomatous autoimmune MG by performing a systematic review and analysis of the literature. Process. Identification and selection of studies.We searched the National Library of Medicine's Medline database from 1966 to February 1998 using the medical subject headings "myasthenia gravis" (restricted to the surgery subheading) and "thymectomy."To identify articles published before 1966, or missed by our original search strategy, we reviewed the references of the identified articles.We classified the resulting articles into the following categories: Class II, controlled but nonrandomized studies describing outcomes in MG patients with and without thymectomy; and Class III, uncontrolled case series describing outcomes in patients with or without thymectomy.Within a given controlled (Class II) study, we planned to describe the therapeutic effect of thymectomy by comparing the rate MG patients receiving thymectomy achieved desirable outcomes with the rate MG patients not receiving thymectomy achieved desirable outcomes.The nonrandomized nature of Class II studies often introduces differences in the baseline characteristics of the thymectomy and nonthymectomy patient groups that can effect MG outcomes independent of thymectomy.To the extent possible, we planned to adjust for these confounding differences in baseline prognostic characteristics.In the absence of randomized controlled trials, such adjustments are critical for estimating the actual therapeutic effect, if any, of thymectomy.6 Between uncontrolled (Class III) studies, comparisons of outcome rates in thymectomy and nonthymectomy MG patients introduce additional confounding baseline differences.6 These additional confounders include institutional, geographic, and historical variations that potentially impact MG patient outcomes independent of thymectomy.Because these additional confounders are difficult to identify and adjust for, outcome comparisons between uncontrolled studies are particularly unreliable.7 For this reason, we excluded Class III studies from further consideration. Abstracted study characteristics.From the controlled studies describing outcomes we abstracted the following characteristics: method and setting of cohort assembly, years during which patients were enrolled in the cohort, number of subjects assembled, duration of follow-up, proportion of subjects lost to follow-up, and the thymectomy techniques employed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Epidemiology: A Basic Science for Clinical Medicine.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-825_9 · Cited by 3,476
Oosterhuis, H. (1997) · Cited by 2,397
MYASTHENIA GRAVIS AND TUMORS OF THE THYMIC REGION: REPORT OF A CASE IN WHICH THE TUMOR WAS REMOVED
BLALOCK, A., MASON, M. F., MORGAN, H. J., & RIVEN, S. S. (1939) · Annals of Surgery · doi:10.1097/00000658-193910000-00005 · Cited by 494
Induction and Intuition in Scientific Thought
Medawar, P. B. (2013) · Routledge eBooks · doi:10.4324/9780203706299 · Cited by 444
The Course of Myasthenia Gravis and Therapies Affecting Outcomea
GROB, D., ARSURA, E. L., BRUNNER, N. G., & NAMBA, T. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb51317.x · Cited by 351
AN EVALUATION OF THYMECTOMY IN MYASTHENIA GRAVIS
SIMPSON, J. A. (1958) · Brain · doi:10.1093/brain/81.1.112 · Cited by 238
THE NATURAL COURSE OF MYASTHENIA GRAVIS AND EFFECT OF THERAPEUTIC MEASURES
Grob, D., Brunner, N. G., & Namba, T. (1981) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1981.tb33764.x · Cited by 171
A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy
Mantegazza, R., Beghi, E., Pareyson, D., Antozzi, C. G., Peluchetti, D., Sghirlanzoni, A., Cosi, V., Lombardi, M., Piccolo, G., Tonali, P., et al. (1990) · Journal of Neurology · doi:10.1007/bf00315656 · Cited by 117
COURSE AND MANAGEMENT OF MYASTHENIA GRAVIS
Grob, D. (1953) · JAMA · doi:10.1001/jama.1953.02940230001001 · Cited by 115
MYASTHENIA GRAVIS AND TUMORS OF THE THYMIC REGION
Blalock Alfred Mason, M. F., J., M., & Riven, S. S. (1943) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-194302000-00016 · Cited by 97
Cited by
Myasthenia gravis: subgroup classification and therapeutic strategies
Gilhus, N. E., & Verschuuren, J. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00145-3 · Cited by 1,267
Gilhus, N. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1602678 · Cited by 1,048
Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. G. M. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0079-y · Cited by 953
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Meriggioli, M. N., & Sanders, D. B. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70063-8 · Cited by 894
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
Kreitzer, A. C., & Malenka, R. C. (2007) · Nature · doi:10.1038/nature05506 · Cited by 735
Myasthenia gravis: past, present, and future
Conti-Fine, B. M., Milani, M., & Kaminski, H. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29894 · Cited by 691
Alexander, G. E. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.3/galexander · Cited by 523
Guidelines for treatment of autoimmune neuromuscular transmission disorders
Skeie, G. O., Apostolski, S., Evoli, A., Gilhus, N. E., Illa, I., Harms, L., Hilton‐Jones, D., Melms, A., Verschuuren, J., & Horge, H. W. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03019.x · Cited by 515
Vincent, A., Palace, J., & Hilton-Jones, D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05186-2 · Cited by 452
Unravelling the pathogenesis of myasthenia gravis
Vincent, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri916 · Cited by 414
Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model
Luo, J., Kaplitt, M. G., Fitzsimons, H. L., Zuzga, D. S., Liu, Y., Oshinsky, M. L., & During, M. J. (2002) · Science · doi:10.1126/science.1074549 · Cited by 325
Clinical gene therapy using recombinant adeno-associated virus vectors
Mueller, C., & Flotte, T. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.68 · Cited by 313
Melzer, N., Ruck, T., Fuhr, P., Gold, R., Hohlfeld, R., Marx, A., Melms, A., Tackenberg, B., Schalke, B., Schneider-Gold, C., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8045-z · Cited by 292
Clinical evaluation and management of myasthenia gravis
Keesey, J. C. (2004) · Muscle & Nerve · doi:10.1002/mus.20030 · Cited by 285
Stefurak, T., Mikulis, D., Mayberg, H., Lang, A. E., Hevenor, S., Pahapill, P., Saint‐Cyr, J., & Lozano, A. (2003) · Movement Disorders · doi:10.1002/mds.10593 · Cited by 215
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease
Feigin, A., Kaplitt, M. G., Tang, C., Lin, T., Mattis, P., Dhawan, V., During, M. J., & Eidelberg, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706006104 · Cited by 181
Metadata
- Authors
- Gronseth, G. S., & Barohn, R. J.
- Venue
- Neurology
- Published
- 2000-07-12
- Volume
- 55
- Issue
- 1
- Pages
- 7-15
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2066239289
- Cited by
- 576
- References
- 11
- FWCI
- 14.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.